High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation

被引:81
作者
Pelat, Thibaut
Hust, Michael
Laffly, Ernmanuelle
Condemine, Florence
Bottex, Chantal
Vidal, Dominique
Lefranc, Marie-Paule
Duebel, Stefan
Thullier, Philippe
机构
[1] Ctr Rech Serv Sante Armees, Dept Biol Agents Transmissibles, Grp Biotechnol Anticorps, F-37802 La Tronche, France
[2] Univ Montpellier 2, LIGM, CNRS, UPR 1142,Inst Genet Humaine, Montpellier, France
[3] Inst Univ France, Paris, France
[4] Tech Univ Carolo Wilhelmina Braunschweig, Inst Biochem & Biotechnol, Braunschweig, Germany
关键词
D O I
10.1128/AAC.01528-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The anthrax lethal toxin (LT) consists of two subunits, the protective antigen (PA) and the lethal factor (LF), and is essential for anthrax pathogenesis. Several recombinant antibodies directed against PA and intended for medical use have been obtained, but none against LF, despite the recommendations of anthrax experts. Here we describe an anti-LF single-chain variable fragment (scFv) that originated from an immunized macaque (Macaca fascicularis) and was obtained by phage display. Panning of the library of 1.8 X 10(8) clones allowed the isolation of 2LF, a high-affinity (equilibrium dissociation constant, 1.02 nM) scFv, which is highly neutralizing in the standardized in vitro assay (50% inhibitory concentration, 1.20 +/- 0.06 nM) and in an in vivo assay. The scFv neutralizes anthrax LT by inhibiting the formation of the LF-PA complex. The genes encoding 2LF are very similar to those of human immunoglobulin germ line genes, sharing substantial (84.2%) identity with their most similar, germinally encoded counterparts; this feature favors medical applications. These results, and others formerly published, demonstrate that our approach can generate antibody fragments suitable for prophylaxis and therapeutics.
引用
收藏
页码:2758 / 2764
页数:7
相关论文
共 60 条
  • [1] Methods for the generation of chicken monoclonal antibody fragments by phage display
    Andris-Widhopf, J
    Rader, C
    Steinberger, P
    Fuller, R
    Barbas, CF
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 242 (1-2) : 159 - 181
  • [2] Selection of Bacillus anthracis isolates resistant to antibiotics
    Athamna, A
    Athamna, M
    Abu-Rashed, N
    Medlej, B
    Bast, DJ
    Rubinstein, E
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 424 - 428
  • [3] Bacillus anthracis, a bug with attitude!
    Baillie, L
    Read, TD
    [J]. CURRENT OPINION IN MICROBIOLOGY, 2001, 4 (01) : 78 - 81
  • [4] Past, imminent and future human medical countermeasures for anthrax
    Baillie, L. W. J.
    [J]. JOURNAL OF APPLIED MICROBIOLOGY, 2006, 101 (03) : 594 - 606
  • [5] BAILLIE LSL, 2003, EXPERT CONSULTATION
  • [6] In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones
    Brook, I
    Elliott, TB
    Pryor, HI
    Sautter, TE
    Gnade, BT
    Thakar, JH
    Knudson, GB
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (06) : 559 - 562
  • [7] Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies
    Brossier, F
    Lévy, M
    Landier, A
    Lafaye, P
    Mock, M
    [J]. INFECTION AND IMMUNITY, 2004, 72 (11) : 6313 - 6317
  • [8] Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice:: characterization of the model and safety studies
    Bugelski, PJ
    Herzyk, DJ
    Rehm, S
    Harmsen, AG
    Gore, EV
    Williams, DM
    Maleeff, BE
    Badger, AM
    Truneh, A
    O'Brien, SR
    Macia, RA
    Wier, PJ
    Morgan, DG
    Hart, TK
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (04): : 230 - 243
  • [9] IMPROVED OLIGONUCLEOTIDE SITE-DIRECTED MUTAGENESIS USING M13 VECTORS
    CARTER, P
    BEDOUELLE, H
    WINTER, G
    [J]. NUCLEIC ACIDS RESEARCH, 1985, 13 (12) : 4431 - 4443
  • [10] Passive antibody administration (immediate immunity) as a specific defense against biological weapons
    Casadevall, A
    [J]. EMERGING INFECTIOUS DISEASES, 2002, 8 (08) : 833 - 841